INVO Fertility, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steven Shum
- Full Time Employees
- 30
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 5582 Broadcast Court Sarasota FL United States of America 34240
- IPO Date
- Nov 2, 2020
- CIK
- 0001417926
- Website
- invobioscience.com
- Similar Companies
- Business
- INVO Fertility, Inc., previously known as NAYA Biosciences, Inc., operates as a healthcare enterprise dedicated to expanding access to advanced reproductive technologies. This organization focuses on establishing, acquiring, and managing fertility clinics, including specialized “INVO Centers” that predominantly feature the intravaginal culture (IVC) procedure. This unique treatment is facilitated by its patented INVOcell® medical device, which enables fertilization and early embryo development to occur within a woman’s body, offering a more intimate, natural, and cost-effective alternative to conventional in vitro fertilization (IVF). INVO Fertility maintains a presence with its centers across the United States and also distributes the INVOcell system to other fertility clinics. In April 2025, the company strategically refocused its operations, divesting its oncology segment, NAYA Therapeutics, to concentrate solely on advancing fertility solutions. Recent initiatives include expanding telehealth options and incorporating Platelet-Rich Plasma (PRP) therapy to broaden patient care. The company has demonstrated strong revenue growth, with its Q3 2025 total revenue increasing by 23% year-over-year, and INVOcell device revenue seeing a 130% increase year-over-year.
INVO Fertility Announces Fiscal Year 2025 Financial Results
INVO Fertility Receives Nasdaq Notification Regarding Late Filing of Annual Report on Form 10-K
INVO Fertility Announces a 1:5 Reverse Stock Split Effective Pre-Market Opening on March 27, 2026
Comparing INVO Fertility (NASDAQ:IVF) & Revolutions Medical (OTCMKTS:RMCP)
INVO Fertility, Inc (NASDAQ:IVF) Sees Large Growth in Short Interest
INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic
INVO Fertility's Wisconsin Clinic Joins Progyny Network
INVO Fertility Closes Acquisition of Indiana-Based Fertility Clinic “Family Beginnings”
INVO Fertility Announces Patent Issuance for Modified INVOcell® Device
INVO Fertility (NASDAQ:IVF) and Minerva Surgical (NASDAQ:UTRS) Head-To-Head Analysis
INVO Fertility Issues Shareholder Letter Highlighting Strengthened Fundamental Position and Strategic Outlook for Growth
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
INVO Fertility to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026
Comparing Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) & INVO Fertility (NASDAQ:IVF)
INVO Fertility Signs Definitive Purchase Agreement to Acquire Indiana-Based Fertility Clinic “Family Beginnings”
INVO Fertility Announces Pricing of $4.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
INVO Fertility Announces Intent to Acquire Indiana-Based Fertility Clinic “Family Beginnings”
INVO Fertility Announces a 1:8 Reverse Stock Split Effective Pre-Market Opening on November 28, 2025
INVO Fertility Announces Third Quarter 2025 Financial Results
INVO Fertility Partners with Heidi Health to Bring AI-Powered Tools to INVO's Wisconsin Fertility Institute